Obefazimod
产品说明书
 |
同义名 : | Abx464; SPL-464; BX-464 |
| CAS号 : | 1258453-75-6 | |
| 货号 : | A722436 | |
| 分子式 : | C16H10ClF3N2O | |
| 纯度 : | 99%+ | |
| 分子量 : | 338.71 | |
| MDL号 : | MFCD31657325 | |
| 存储条件： |
Pure form Sealed in dry,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Obefazimod effectively suppresses HIV-1 production in cells infected with PBMC and macrophages. It exhibits robust inhibitory action against all tested HIV-1 subtypes, including B, C, and recombinant forms. Obefazimod also strongly prevents the replication of viral strains that possess mutations granting resistance to various therapeutic drugs in vitro. Unlike the antiviral medication 3TC, which shows limited activity against K65R and M184V mutant strains, Obefazimod successfully inhibits both. In an effort to extend the understanding of Obefazimod's impact on HIV-1 replication in other primary cells, treatments range from 0.01 μM to 30 μM of Obefazimod, with monitoring of p24 antigen levels in culture supernatants across a span of 12 days. Obefazimod demonstrates a dose-responsive blockade of virus replication, with an IC50 value between 0.1 μM and 1 μM[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.95mL 0.59mL 0.30mL |
14.76mL 2.95mL 1.48mL |
29.52mL 5.90mL 2.95mL |
| 参考文献 |
|---|